vs
AVANOS MEDICAL, INC.（AVNS）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是STURM RUGER & CO INC的1.2倍（$180.9M vs $151.1M），STURM RUGER & CO INC同比增速更快（3.6% vs 0.7%），AVANOS MEDICAL, INC.自由现金流更多（$21.3M vs $12.3M），过去两年STURM RUGER & CO INC的营收复合增速更高（5.1% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
AVNS vs RGR — 直观对比
营收规模更大
AVNS
是对方的1.2倍
$151.1M
营收增速更快
RGR
高出2.9%
0.7%
自由现金流更多
AVNS
多$9.0M
$12.3M
两年增速更快
RGR
近两年复合增速
4.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $151.1M |
| 净利润 | $-1.3M | — |
| 毛利率 | 47.5% | 17.8% |
| 营业利润率 | 1.4% | 2.3% |
| 净利率 | -0.7% | — |
| 营收同比 | 0.7% | 3.6% |
| 净利润同比 | 99.7% | — |
| 每股收益（稀释后） | $-0.02 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSRGR
| Q4 25 | $180.9M | $151.1M | ||
| Q3 25 | $177.8M | $126.8M | ||
| Q2 25 | $175.0M | $132.5M | ||
| Q1 25 | $167.5M | $135.7M | ||
| Q4 24 | $179.6M | $145.8M | ||
| Q3 24 | $170.4M | $122.3M | ||
| Q2 24 | $171.7M | $130.8M | ||
| Q1 24 | $166.1M | $136.8M |
净利润AVNSRGR
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | $1.6M | ||
| Q2 25 | $-76.8M | $-17.2M | ||
| Q1 25 | $6.6M | $7.8M | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | $4.7M | ||
| Q2 24 | $1.8M | $8.3M | ||
| Q1 24 | $-900.0K | $7.1M |
毛利率AVNSRGR
| Q4 25 | 47.5% | 17.8% | ||
| Q3 25 | 48.4% | 15.1% | ||
| Q2 25 | 52.6% | 3.9% | ||
| Q1 25 | 53.6% | 22.0% | ||
| Q4 24 | 54.6% | 22.8% | ||
| Q3 24 | 54.5% | 18.5% | ||
| Q2 24 | 55.7% | 22.3% | ||
| Q1 24 | 57.1% | 21.5% |
营业利润率AVNSRGR
| Q4 25 | 1.4% | 2.3% | ||
| Q3 25 | 0.1% | -2.7% | ||
| Q2 25 | -42.6% | -15.6% | ||
| Q1 25 | 6.1% | 6.2% | ||
| Q4 24 | -233.0% | 7.8% | ||
| Q3 24 | 7.0% | 3.1% | ||
| Q2 24 | 3.7% | 6.9% | ||
| Q1 24 | 2.4% | 5.5% |
净利率AVNSRGR
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | 1.2% | ||
| Q2 25 | -43.9% | -13.0% | ||
| Q1 25 | 3.9% | 5.7% | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | 3.9% | ||
| Q2 24 | 1.0% | 6.3% | ||
| Q1 24 | -0.5% | 5.2% |
每股收益（稀释后）AVNSRGR
| Q4 25 | $-0.02 | $0.22 | ||
| Q3 25 | $-0.03 | $0.10 | ||
| Q2 25 | $-1.66 | $-1.05 | ||
| Q1 25 | $0.14 | $0.46 | ||
| Q4 24 | $-8.64 | $0.62 | ||
| Q3 24 | $0.09 | $0.28 | ||
| Q2 24 | $0.04 | $0.47 | ||
| Q1 24 | $-0.02 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $92.5M |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $283.8M |
| 总资产 | $1.1B | $342.0M |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSRGR
| Q4 25 | $89.8M | $92.5M | ||
| Q3 25 | $70.5M | $80.8M | ||
| Q2 25 | $90.3M | $101.4M | ||
| Q1 25 | $97.0M | $108.3M | ||
| Q4 24 | $107.7M | $105.5M | ||
| Q3 24 | $89.0M | $96.0M | ||
| Q2 24 | $92.2M | $105.6M | ||
| Q1 24 | $75.8M | $115.3M |
总债务AVNSRGR
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSRGR
| Q4 25 | $778.2M | $283.8M | ||
| Q3 25 | $778.0M | $279.6M | ||
| Q2 25 | $776.3M | $289.3M | ||
| Q1 25 | $839.4M | $321.5M | ||
| Q4 24 | $828.5M | $319.6M | ||
| Q3 24 | $1.2B | $314.9M | ||
| Q2 24 | $1.2B | $321.5M | ||
| Q1 24 | $1.2B | $332.0M |
总资产AVNSRGR
| Q4 25 | $1.1B | $342.0M | ||
| Q3 25 | $1.1B | $342.3M | ||
| Q2 25 | $1.0B | $349.5M | ||
| Q1 25 | $1.1B | $379.0M | ||
| Q4 24 | $1.2B | $384.0M | ||
| Q3 24 | $1.7B | $373.5M | ||
| Q2 24 | $1.7B | $376.7M | ||
| Q1 24 | $1.7B | $385.0M |
负债/权益比AVNSRGR
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $12.3M |
| 自由现金流率自由现金流/营收 | 11.8% | 8.2% |
| 资本支出强度资本支出/营收 | 3.8% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | $38.5M |
8季度趋势，按日历期对齐
经营现金流AVNSRGR
| Q4 25 | $28.2M | $15.5M | ||
| Q3 25 | $14.0M | $12.9M | ||
| Q2 25 | $6.8M | $14.7M | ||
| Q1 25 | $25.7M | $11.1M | ||
| Q4 24 | $57.9M | $20.0M | ||
| Q3 24 | $23.0M | $9.4M | ||
| Q2 24 | $27.8M | $18.7M | ||
| Q1 24 | $-8.0M | $7.3M |
自由现金流AVNSRGR
| Q4 25 | $21.3M | $12.3M | ||
| Q3 25 | $7.0M | $7.0M | ||
| Q2 25 | $-4.2M | $9.1M | ||
| Q1 25 | $19.0M | $10.0M | ||
| Q4 24 | $53.1M | $16.4M | ||
| Q3 24 | $20.0M | $2.6M | ||
| Q2 24 | $21.9M | $10.1M | ||
| Q1 24 | $-12.1M | $5.6M |
自由现金流率AVNSRGR
| Q4 25 | 11.8% | 8.2% | ||
| Q3 25 | 3.9% | 5.5% | ||
| Q2 25 | -2.4% | 6.9% | ||
| Q1 25 | 11.3% | 7.4% | ||
| Q4 24 | 29.6% | 11.2% | ||
| Q3 24 | 11.7% | 2.1% | ||
| Q2 24 | 12.8% | 7.7% | ||
| Q1 24 | -7.3% | 4.1% |
资本支出强度AVNSRGR
| Q4 25 | 3.8% | 2.1% | ||
| Q3 25 | 3.9% | 4.6% | ||
| Q2 25 | 6.3% | 4.2% | ||
| Q1 25 | 4.0% | 0.8% | ||
| Q4 24 | 2.7% | 2.5% | ||
| Q3 24 | 1.8% | 5.5% | ||
| Q2 24 | 3.4% | 6.6% | ||
| Q1 24 | 2.5% | 1.3% |
现金转化率AVNSRGR
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | 1.98× | ||
| Q2 24 | 15.44× | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
